Study Summary
This trial will test the efficacy of a triple combination therapy for lung cancer patients who have previously been treated with other immunotherapy.
- Non-Small Cell Lung Cancer
- Non-Small Cell Carcinoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 6 Secondary · Reporting Duration: Through completion of follow-up (estimated to be 5 years)
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Cohort A: Zimberelimab + Domvanalimab + Etrumadenant
1 of 2
Cohort B: Zimberelimab + Domvanalimab + Etrumadenant
1 of 2
Experimental Treatment
30 Total Participants · 2 Treatment Groups
Primary Treatment: Etrumadenant · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many participants have enrolled in this experiment thus far?
"Affirmative. Clinicaltrials.gov records demonstrate that this clinical trial, which was first introduced on August 4th 2021 is presently recruiting participants. The study seeks to enlist thirty people from a single medical centre." - Anonymous Online Contributor
Are individuals being enrolled in this trial presently?
"Affirmative. Research hosted on clinicaltrials.gov reveals that this investigation, which was initially published on August 4th 2021, is still accepting participants. Approximately 30 individuals are needed to be sourced from 1 location." - Anonymous Online Contributor
To what extent could Zimberelimab be detrimental to patients?
"Considering the drug is in a Phase 2 trial, with some evidence of safety but no proof of efficacy yet, our team at Power rated Zimberelimab's safety as a 2 on their rating scale." - Anonymous Online Contributor